Mirabegron Cardiovascular Safety and Monitoring

Blood Pressure Effects

Common Adverse Events

Monitoring Recommendations

Clinical Misconception and Practical Guidance

Mirabegron for Neurogenic Bladder Treatment

FDA-Approved Indication and Clinical Guidelines

• The American Urological Association distinguishes mirabegron from guidelines for non-neurogenic OAB, which explicitly exclude neurogenic bladder populations, as mirabegron is approved for neurogenic detrusor overactivity in pediatric patients aged 3 years and older weighing ≥35 kg 2

Safety Monitoring and Adverse Events

• The European Medical Agency recommends monitoring blood pressure periodically, especially during initial treatment, as mirabegron can cause dose-dependent blood pressure increases 3
• The American Academy of Pediatrics advises administering mirabegron with caution in patients with bladder outlet obstruction due to risk of urinary retention, and monitoring post-void residual volume regularly 3
• The National Institute for Health and Care Excellence suggests advising patients to discontinue mirabegron if worsening voiding symptoms or urinary stream occurs 4